Bill Facteau - 23 Apr 2025 Form 4 Insider Report for BioCardia, Inc. (BCDA)

Reporting relationship: Director
Issuer ticker: BCDA
Reported as of: 23 Apr 2025
Net transaction value: +$24,999
SEC form: 4
Accepted by SEC: 25 Apr 2025, 21:37:32 UTC
Prior SEC filing: 16 Oct 2024
Next SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ David McClung, by power of attorney

Key filing fact

Bill Facteau filed Form 4 for BioCardia, Inc. (BCDA) on 25 Apr 2025.

Key facts

This page summarizes Bill Facteau's Form 4 filing for BioCardia, Inc. (BCDA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Apr 2025, 21:37.

Change

Previous filing in this sequence was filed on 16 Oct 2024.
Current net transaction value: +$24,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCDA transaction

Common Stock

Purchase

Transaction value: $24,999
Shares: +13,123
Change %
Price: $1.90
Shares after: 13,123
Date: 23 Apr 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCDA transaction Derivative

Warrant (right to buy)

Purchase

Transaction value
Shares: +13,123
Change %
Price
Shares after: 13,123
Date: 23 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,123
Exercise price: $1.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.